Providing a VOICE for Indiana's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 2009
Meetings & Education
State Society Education Series
IOS Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Off-Label Use Literature
National Professional Organizations
IOS Corporate Members
Become a Supporter
Industry News Archive
FDA Approves Pembrolizumab for Treatment of PMBCL
On June 13, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy.
Read the FDA press release here.
Tweets by IN_Oncology